AXT is in a violent, high-volatility uptrend that has recently rolled over into a sharp corrective phase. The stock is up 506.7% over the trailing year and 206.3% year-to-date, yet at $51.33 it sits only about 32% of the way through its 52-week range of $7.80 to $143.16 — meaning it has already surrendered roughly two-thirds of its peak-to-trough advance from the high. That positioning is characteristic of a parabolic momentum name that has broken down rather than a stock consolidating near highs; the 73.75% maximum drawdown confirms the severity of the de-rating from the $143 peak. The 1-year relative strength of +496.3 percentage points versus SPY underscores how extreme the prior run was, and how much air remains beneath the price if the trend structure fails.\n\nShort-term momentum is decisively negative and diverging sharply from the still-positive annual trend. The stock is down 40.2% over the past month, 25.2% over three months and 52.7% over six months, versus a 1-year gain of 506.7% — a classic deceleration pattern where the trailing-year number is a stale artifact of the first-half melt-up. Relative strength is deeply negative across every short window (-38.2 pts vs SPY over 1 month, -23.2 pts over 3 months, -55.8 pts over 6 months), indicating the stock is being sold aggressively even as the broader market is roughly flat (SPY -1.99% over 1 month). The lone bright spot is the most recent session, with a +6.49% bounce off the $48.20 prior close on elevated volume of 11.5 million shares — a potential short-term capitulation/oversold signal, but one that has yet to reverse the intermediate downtrend.\n\nKey technical levels are well defined by the 52-week envelope. Immediate support sits at the recent $48.20 close and the $45.57-$46.94 zone carved out in mid-to-late July, with the ultimate floor at the $7.80 52-week low far below; resistance is layered at the $60-$65 area (October breakdown zone) and then the $85-$96 region where the stock repeatedly failed in August and October, with the $143.16 high as the long-term ceiling. A reclaim of $65 would suggest the correction is basing, while a break below $45 would open the door to a retest of the $36.97 July low. With a beta of 2.01, the stock is roughly twice as volatile as the market, meaning position sizing must be materially smaller than a benchmark-weight allocation and stop-loss discipline is paramount given the 73.75% drawdown already realized.

The revenue trajectory has inflected from stagnation to explosive growth. Q3 2026 revenue reached $73.41 million, up 162.6% year-over-year from $27.96 million in Q3 2025, and up 54% sequentially from Q2's $47.59 million, which itself was up 77% from Q1's $26.92 million. The sequential cadence — $26.9M → $47.6M → $73.4M — shows acceleration, not just recovery, and the segment mix confirms substrates ($37.56M) are the larger driver versus raw materials and other ($10.03M) in the disclosed period. This is a genuine demand-driven ramp tied to AI optical infrastructure rather than a one-off, though the steepness of the curve raises the question of how much is pull-forward versus sustainable run-rate.\n\nProfitability has swung from deeply negative to robust in three quarters. Q3 2026 net income was $25.72 million (a 35.0% net margin) versus a loss of $1.62 million in Q1 2026 and a loss of $1.91 million in Q3 2025. Gross margin expanded from 29.6% in Q1 to 44.9% in Q2 to 56.0% in Q3 — a dramatic operating-leverage story as fixed costs are absorbed by volume. Operating margin reached 38.7% in Q3, and EBITDA of $34.32 million (46.8% EBITDA margin) dwarfs the negative EBITDA of prior quarters. Note the discrepancy between the trailing metrics (net margin -24.1%, gross margin 12.7%, operating margin -24.9%) and the latest quarter — the trailing figures are heavily distorted by the loss-making first half and prior year, so the forward earnings power is far better than the TTM snapshot implies.\n\nThe balance sheet has been transformed by a large capital raise. The Q2 2026 cash flow statement shows $600.6 million of common stock issued and $621.4 million of net financing inflow, lifting cash to $445.2 million from $57.9 million — a massive liquidity cushion that funds growth but came at the cost of dilution (shares outstanding rose from 53.3 million in Q1 to 63.8 million in Q3). Debt-to-equity is low at 0.237 and the current ratio is strong at 2.72, so financial risk is minimal. The concern is cash generation: TTM free cash flow is -$19.57 million, Q2 FCF was only $3.56 million despite $13.0 million of net income, and working capital consumed $16.3 million as inventory and receivables ballooned — inventory days are elevated (289 days per the Q3 ratio data), meaning the company is funding a working-capital build. ROE is -7.8% on a trailing basis, reflecting the loss-making history, but the forward trajectory is clearly positive.